Coeptis Therapeutics (NASDAQ:ZSQR) Shares Up 8.9% – What’s Next?

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) shot up 8.9% during mid-day trading on Wednesday . The company traded as high as $11.52 and last traded at $11.52. 136,898 shares were traded during trading, a decline of 31% from the average session volume of 197,687 shares. The stock had previously closed at $10.58.

Analysts Set New Price Targets

Separately, Wall Street Zen lowered Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Coeptis Therapeutics currently has an average rating of “Sell”.

Coeptis Therapeutics Price Performance

The company’s 50 day simple moving average is $12.24 and its 200 day simple moving average is $12.68. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.25 and a quick ratio of 3.25. The stock has a market cap of $579.62 million, a P/E ratio of -4.47 and a beta of -0.22.

Coeptis Therapeutics (NASDAQ:ZSQR) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share (EPS) for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.The business had revenue of $0.11 million during the quarter.

Institutional Investors Weigh In On Coeptis Therapeutics

Institutional investors have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC grew its stake in Coeptis Therapeutics by 100.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after purchasing an additional 2,500 shares in the last quarter. Yorkville Advisors Global LP acquired a new position in shares of Coeptis Therapeutics during the 3rd quarter worth approximately $140,000. Marshall Wace LLP bought a new stake in shares of Coeptis Therapeutics during the 4th quarter worth approximately $259,000. State Street Corp raised its stake in shares of Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after purchasing an additional 6,962 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after buying an additional 4,721 shares during the last quarter. Institutional investors own 13.88% of the company’s stock.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.